Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317610

SCHEMBL25317610

SCHEMBL25317610

CS(=O)(=O)c1ccc(OCCN2CCC3(CC2)C(=O)Nc2ccc(C#N)cc23)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 5/20 0.44
▸ TRPV4 Q9HBA0 4/20 0.41
▸ TRPM8 Q7Z2W7 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PGR P06401 4/20 0.38
▸ KCNA5 P22460 2/20 0.37
▸ HTR1A P08908 2/20 0.37
▸ HTR2A P28223 2/20 0.37
▸ HTR7 P34969 2/20 0.37
▸ HTR6 P50406 2/20 0.37
▸ HRH1 P35367 1/20 0.37
▸ CCR3 P51677 1/20 0.37
▸ IP6K1 Q92551 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507441 1.00 ALK (0.44) ALKTRPV4TRPM8KDM4EALDH1A1
SCHEMBL25317367 0.91 ALK (0.43) ALKPGRKCNA5HRH1
SCHEMBL30507496 0.90 ALK (0.42) ALKTRPV4PGR
SCHEMBL25317462 0.90 ALK (0.42) ALKTRPV4PGR
SCHEMBL25317519 0.89 IP6K1 (0.44) KDM4EALDH1A1HTR1AHTR2AHTR7
SCHEMBL30506909 0.89 IP6K1 (0.44) KDM4EALDH1A1HTR1AHTR2AHTR7
SCHEMBL25932861 0.88 KDM4E (0.41) ALKKDM4EALDH1A1KCNA5HTR1A
SCHEMBL30507207 0.88 ALK (0.42) ALKTRPV4PGRKCNA5HRH1
SCHEMBL25320085 0.88 ALK (0.42) ALKTRPV4PGRKCNA5HRH1
SCHEMBL25315787 0.88 ALK (0.41) ALKTRPV4PGRKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR ALK 4587/4885TRPV4 4637/4885TRPM8 3469/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 ALK 4572/4885TRPV4 4647/4885TRPM8 3516/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR ALK 4587/4885TRPV4 4637/4885TRPM8 3469/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALK 4572/4885TRPV4 4647/4885TRPM8 3516/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALK 4572/4885TRPV4 4647/4885TRPM8 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.